# üåê External Evidence - –ó–∞—á–µ–º –∏ –ö–∞–∫?

## üìã –ß—Ç–æ —ç—Ç–æ —Ç–∞–∫–æ–µ?

**External Evidence** - —ç—Ç–æ –¥–∞–Ω–Ω—ã–µ –∏–∑ –≤–Ω–µ—à–Ω–∏—Ö –ø—É–±–ª–∏—á–Ω—ã—Ö –∏—Å—Ç–æ—á–Ω–∏–∫–æ–≤, –∫–æ—Ç–æ—Ä—ã–µ –º—ã –∞–≤—Ç–æ–º–∞—Ç–∏—á–µ—Å–∫–∏ —Å–æ–±–∏—Ä–∞–µ–º –∏ –∏—Å–ø–æ–ª—å–∑—É–µ–º –¥–ª—è –æ–±–æ–≥–∞—â–µ–Ω–∏—è AI-–≥–µ–Ω–µ—Ä–∏—Ä—É–µ–º—ã—Ö –¥–æ–∫—É–º–µ–Ω—Ç–æ–≤.

---

## üéØ –ó–∞—á–µ–º –Ω—É–∂–Ω–æ?

### 1. **Evidence-Based Medicine** üìä
Regulatory –¥–æ–∫—É–º–µ–Ω—Ç—ã (IB, Protocol) –¥–æ–ª–∂–Ω—ã –±—ã—Ç—å –æ—Å–Ω–æ–≤–∞–Ω—ã –Ω–∞ **–Ω–∞—É—á–Ω—ã—Ö –¥–æ–∫–∞–∑–∞—Ç–µ–ª—å—Å—Ç–≤–∞—Ö**, –∞ –Ω–µ –ø—Ä–æ—Å—Ç–æ –Ω–∞ –º–Ω–µ–Ω–∏—è—Ö –∏–ª–∏ –ø—Ä–µ–¥–ø–æ–ª–æ–∂–µ–Ω–∏—è—Ö.

**–†–µ–≥—É–ª—è—Ç–æ—Ä—ã (FDA, EMA) —Ç—Ä–µ–±—É—é—Ç:**
- –°—Å—ã–ª–∫–∏ –Ω–∞ –æ–ø—É–±–ª–∏–∫–æ–≤–∞–Ω–Ω—ã–µ –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏—è
- –î–∞–Ω–Ω—ã–µ –∏–∑ –ø–æ—Ö–æ–∂–∏—Ö clinical trials
- –ò–∑–≤–µ—Å—Ç–Ω—ã–µ safety –¥–∞–Ω–Ω—ã–µ –æ –ø—Ä–µ–ø–∞—Ä–∞—Ç–µ

### 2. **–≠–∫–æ–Ω–æ–º–∏—è –≤—Ä–µ–º–µ–Ω–∏ Medical Writers** ‚è±Ô∏è
–í–º–µ—Å—Ç–æ —Ç–æ–≥–æ —á—Ç–æ–±—ã –≤—Ä—É—á–Ω—É—é:
- –ò—Å–∫–∞—Ç—å –ø—É–±–ª–∏–∫–∞—Ü–∏–∏ –≤ PubMed
- –ê–Ω–∞–ª–∏–∑–∏—Ä–æ–≤–∞—Ç—å ClinicalTrials.gov
- –ü—Ä–æ–≤–µ—Ä—è—Ç—å FDA adverse events

**AI –¥–µ–ª–∞–µ—Ç —ç—Ç–æ –∞–≤—Ç–æ–º–∞—Ç–∏—á–µ—Å–∫–∏ –∑–∞ —Å–µ–∫—É–Ω–¥—ã!**

### 3. **–ö–∞—á–µ—Å—Ç–≤–æ –∏ Compliance** ‚úÖ
- –î–æ–∫—É–º–µ–Ω—Ç—ã —Å references –≤—ã–≥–ª—è–¥—è—Ç –ø—Ä–æ—Ñ–µ—Å—Å–∏–æ–Ω–∞–ª—å–Ω–µ–µ
- Regulatory reviewers –≤–∏–¥—è—Ç, —á—Ç–æ –≤—ã —Å–¥–µ–ª–∞–ª–∏ homework
- –°–Ω–∏–∂–∞–µ—Ç—Å—è —Ä–∏—Å–∫ rejection –∏–∑-–∑–∞ –Ω–µ–¥–æ—Å—Ç–∞—Ç–æ—á–Ω–æ–π evidence base

### 4. **–ö–æ–Ω—Ç–µ–∫—Å—Ç –¥–ª—è AI** ü§ñ
GPT-4 –≥–µ–Ω–µ—Ä–∏—Ä—É–µ—Ç **–ª—É—á—à–∏–π –∫–æ–Ω—Ç–µ–Ω—Ç**, –∫–æ–≥–¥–∞ —É –Ω–µ–≥–æ –µ—Å—Ç—å:
- –†–µ–∞–ª—å–Ω—ã–µ –¥–∞–Ω–Ω—ã–µ –∏–∑ –ø–æ—Ö–æ–∂–∏—Ö trials
- –ù–∞—É—á–Ω—ã–µ –ø—É–±–ª–∏–∫–∞—Ü–∏–∏ –ø–æ indication
- Safety –¥–∞–Ω–Ω—ã–µ –æ –ø—Ä–µ–ø–∞—Ä–∞—Ç–µ

---

## üîç –ß—Ç–æ –∏–º–µ–Ω–Ω–æ —Å–æ–±–∏—Ä–∞–µ–º?

### 1. **ClinicalTrials.gov** üè•

**–ß—Ç–æ –∏—â–µ–º:**
- –ü–æ—Ö–æ–∂–∏–µ clinical trials –ø–æ indication (–Ω–∞–ø—Ä–∏–º–µ—Ä, "Type 2 Diabetes")
- Trials –≤ —Ç–æ–π –∂–µ —Ñ–∞–∑–µ (Phase 2, Phase 3)
- Completed trials —Å —Ä–µ–∑—É–ª—å—Ç–∞—Ç–∞–º–∏

**–ß—Ç–æ –ø–æ–ª—É—á–∞–µ–º:**
```json
{
  "nctId": "NCT12345678",
  "title": "Study of Drug X in Type 2 Diabetes",
  "phase": "Phase 2",
  "status": "Completed",
  "enrollment": 250,
  "primaryOutcome": "HbA1c reduction at 12 weeks",
  "results": "Mean HbA1c reduction: -1.2%"
}
```

**–ö–∞–∫ –∏—Å–ø–æ–ª—å–∑—É–µ–º:**
- –í —Å–µ–∫—Ü–∏–∏ **"Effects in Humans"** IB - –ø–æ–∫–∞–∑—ã–≤–∞–µ–º —á—Ç–æ —É–∂–µ –∏–∑—É—á–µ–Ω–æ
- –í **Protocol** - —Å—Ä–∞–≤–Ω–∏–≤–∞–µ–º –Ω–∞—à –¥–∏–∑–∞–π–Ω —Å —Å—É—â–µ—Å—Ç–≤—É—é—â–∏–º–∏ trials
- –í **Synopsis** - –∫–æ–Ω—Ç–µ–∫—Å—Ç –¥–ª—è –Ω–∞—à–µ–≥–æ –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏—è

**–ü—Ä–∏–º–µ—Ä –≤ IB:**
```markdown
### 7.3 Efficacy

**Evidence from Clinical Trials:**
- Study of Metformin in Type 2 Diabetes (NCT00123456)
  Phase: Phase 3 | Status: Completed
  Primary Outcome: HbA1c reduction at 24 weeks
  Enrollment: 500 participants
  Results: Mean HbA1c reduction of -1.5% vs placebo

- Study of SGLT2 Inhibitor in T2DM (NCT00234567)
  Phase: Phase 2 | Status: Completed
  Primary Outcome: Fasting glucose reduction
  Enrollment: 180 participants
```

---

### 2. **PubMed** üìö

**–ß—Ç–æ –∏—â–µ–º:**
- –ù–∞—É—á–Ω—ã–µ –ø—É–±–ª–∏–∫–∞—Ü–∏–∏ –ø–æ compound name
- –ü—É–±–ª–∏–∫–∞—Ü–∏–∏ –ø–æ indication
- –ú–µ—Ö–∞–Ω–∏–∑–º –¥–µ–π—Å—Ç–≤–∏—è, PK/PD –¥–∞–Ω–Ω—ã–µ

**–ß—Ç–æ –ø–æ–ª—É—á–∞–µ–º:**
```json
{
  "pmid": "12345678",
  "title": "Efficacy and Safety of AST-202 in Type 2 Diabetes",
  "authors": ["Smith J", "Johnson M", "Williams K"],
  "journal": "New England Journal of Medicine",
  "publicationDate": "2024-03-15",
  "abstract": "Background: AST-202 is a novel DPP-4 inhibitor..."
}
```

**–ö–∞–∫ –∏—Å–ø–æ–ª—å–∑—É–µ–º:**
- –í **References** —Å–µ–∫—Ü–∏–∏ IB
- –í **Background/Rationale** Protocol
- –î–ª—è –æ–±–æ—Å–Ω–æ–≤–∞–Ω–∏—è –≤—ã–±–æ—Ä–∞ endpoints
- –î–ª—è –æ–ø–∏—Å–∞–Ω–∏—è mechanism of action

**–ü—Ä–∏–º–µ—Ä –≤ IB:**
```markdown
### 7.3 Efficacy

**Evidence from Published Literature:**

- Efficacy and Safety of AST-202 in Type 2 Diabetes 
  (Smith J et al., NEJM, 2024-03-15)
  Background: AST-202 is a novel DPP-4 inhibitor that 
  demonstrated significant HbA1c reduction in preclinical 
  models. This phase 2 study evaluated...

- Pharmacokinetics of AST-202 in Healthy Volunteers
  (Johnson M et al., Clinical Pharmacology, 2023-11-20)
  AST-202 showed linear PK with t1/2 of 12 hours, 
  supporting once-daily dosing...
```

---

### 3. **openFDA** ‚ö†Ô∏è

**–ß—Ç–æ –∏—â–µ–º:**
- Adverse events –¥–ª—è –Ω–∞—à–µ–≥–æ –ø—Ä–µ–ø–∞—Ä–∞—Ç–∞ (–∏–ª–∏ –∫–ª–∞—Å—Å–∞ –ø—Ä–µ–ø–∞—Ä–∞—Ç–æ–≤)
- Drug interactions
- Safety warnings

**–ß—Ç–æ –ø–æ–ª—É—á–∞–µ–º:**
```json
{
  "drugName": "AST-202",
  "adverseEvents": [
    {
      "term": "Hypoglycemia",
      "frequency": 45,
      "seriousness": "Serious"
    },
    {
      "term": "Nausea",
      "frequency": 123,
      "seriousness": "Non-serious"
    }
  ],
  "receiptDate": "2024-01-15"
}
```

**–ö–∞–∫ –∏—Å–ø–æ–ª—å–∑—É–µ–º:**
- –í **Safety and Tolerability** —Å–µ–∫—Ü–∏–∏ IB
- –í **Risk Assessment** Protocol
- –í **Risks** —Å–µ–∫—Ü–∏–∏ ICF (Informed Consent)
- –î–ª—è –ø–ª–∞–Ω–∏—Ä–æ–≤–∞–Ω–∏—è safety monitoring

**–ü—Ä–∏–º–µ—Ä –≤ IB:**
```markdown
### 7.4 Safety and Tolerability

**Safety Data from FDA Adverse Event Reporting:**

- Hypoglycemia: 45 reports (Serious)
- Nausea: 123 reports (Non-serious)
- Headache: 89 reports (Non-serious)
- Dizziness: 67 reports (Non-serious)
- Diarrhea: 54 reports (Non-serious)

**Common Adverse Events:**
Based on post-marketing surveillance, the most common 
adverse events (‚â•5%) include:
- Hypoglycemia (15%) - mostly mild to moderate
- Nausea (8%) - usually transient
- Headache (6%) - self-limiting
```

---

## üîÑ –ö–∞–∫ —ç—Ç–æ —Ä–∞–±–æ—Ç–∞–µ—Ç? (Technical Flow)

### Step 1: User –Ω–∞–∂–∏–º–∞–µ—Ç "Fetch External Data"
```typescript
// components/fetch-external-data-button.tsx
const handleFetch = async () => {
  const response = await fetch('/api/integrations/fetch-all', {
    method: 'POST',
    body: JSON.stringify({ projectId })
  })
}
```

### Step 2: API –¥–µ–ª–∞–µ—Ç 3 –ø–∞—Ä–∞–ª–ª–µ–ª—å–Ω—ã—Ö –∑–∞–ø—Ä–æ—Å–∞
```typescript
// app/api/integrations/fetch-all/route.ts

// 1. ClinicalTrials.gov
const trials = await ctClient.searchByCondition(
  project.indication, // "Type 2 Diabetes"
  10 // limit
)

// 2. PubMed
const publications = await pubmedClient.search(
  `${project.title} ${project.indication}`, // "AST-202 Type 2 Diabetes"
  10
)

// 3. openFDA
const adverseEvents = await fdaClient.searchAdverseEvents(
  drugName, // "AST-202"
  10
)
```

### Step 3: –î–∞–Ω–Ω—ã–µ —Å–æ—Ö—Ä–∞–Ω—è—é—Ç—Å—è –≤ –ë–î
```sql
-- evidence_sources table
INSERT INTO evidence_sources (
  project_id,
  source,        -- 'ClinicalTrials.gov', 'PubMed', 'openFDA'
  external_id,   -- NCT ID, PMID, etc.
  payload_json   -- Full data
)
```

### Step 4: AI –∏—Å–ø–æ–ª—å–∑—É–µ—Ç –ø—Ä–∏ –≥–µ–Ω–µ—Ä–∞—Ü–∏–∏ –¥–æ–∫—É–º–µ–Ω—Ç–∞
```typescript
// supabase/functions/generate-document/index.ts

// Fetch evidence sources
const { data: evidenceSources } = await supabase
  .from('evidence_sources')
  .select('*')
  .eq('project_id', projectId)

// Parse by source
const clinicalTrials = evidenceSources
  .filter(s => s.source === 'ClinicalTrials.gov')
  .map(s => s.payload_json)

const publications = evidenceSources
  .filter(s => s.source === 'PubMed')
  .map(s => s.payload_json)

const safetyData = evidenceSources
  .filter(s => s.source === 'openFDA')
  .map(s => s.payload_json)

// Pass to prompt
const prompt = generateIBPrompt({
  projectTitle,
  compoundName,
  indication,
  clinicalTrials,    // ‚Üê Used here!
  publications,      // ‚Üê Used here!
  safetyData        // ‚Üê Used here!
})
```

### Step 5: GPT-4 –≥–µ–Ω–µ—Ä–∏—Ä—É–µ—Ç –∫–æ–Ω—Ç–µ–Ω—Ç —Å references
```markdown
### 7.3 Efficacy

**Evidence from Published Literature:**
- Efficacy and Safety of AST-202... (Smith et al., NEJM, 2024)

**Evidence from Clinical Trials:**
- Study of Metformin in T2DM (NCT00123456)
  Phase: Phase 3 | Status: Completed
  Results: HbA1c reduction -1.5%
```

---

## üìä –ì–¥–µ –∏—Å–ø–æ–ª—å–∑—É–µ—Ç—Å—è –≤ –¥–æ–∫—É–º–µ–Ω—Ç–∞—Ö?

### Investigator's Brochure (IB)

#### Section 7.3: Efficacy
- ‚úÖ Publications ‚Üí Literature review
- ‚úÖ Clinical Trials ‚Üí Evidence of efficacy

#### Section 7.4: Safety
- ‚úÖ openFDA ‚Üí Known adverse events
- ‚úÖ Publications ‚Üí Safety data from studies

#### Section 8: Summary
- ‚úÖ All sources ‚Üí Benefit-risk assessment

---

### Clinical Trial Protocol

#### Section 2: Background and Rationale
- ‚úÖ Publications ‚Üí Scientific rationale
- ‚úÖ Clinical Trials ‚Üí Why this study is needed

#### Section 6: Study Endpoints
- ‚úÖ Clinical Trials ‚Üí What others measured
- ‚úÖ Publications ‚Üí Validated endpoints

#### Section 8: Safety Assessments
- ‚úÖ openFDA ‚Üí What to monitor
- ‚úÖ Publications ‚Üí Safety concerns

---

### Informed Consent Form (ICF)

#### Section: Risks
- ‚úÖ openFDA ‚Üí Known side effects
- ‚úÖ Publications ‚Üí Frequency of events

#### Section: Benefits
- ‚úÖ Clinical Trials ‚Üí Potential benefits
- ‚úÖ Publications ‚Üí Evidence of efficacy

---

### Study Synopsis

#### Background
- ‚úÖ Publications ‚Üí Context
- ‚úÖ Clinical Trials ‚Üí Landscape

#### Rationale
- ‚úÖ All sources ‚Üí Why this study matters

---

## üí° –†–µ–∞–ª—å–Ω—ã–π –ø—Ä–∏–º–µ—Ä

### –ü—Ä–æ–µ–∫—Ç: AST-202 Phase 2 Trial for Type 2 Diabetes

#### 1. User —Å–æ–∑–¥–∞–µ—Ç –ø—Ä–æ–µ–∫—Ç:
```
Title: AST-202 Phase 2 Trial
Phase: Phase 2
Indication: Type 2 Diabetes
Compound: AST-202
```

#### 2. User –Ω–∞–∂–∏–º–∞–µ—Ç "Fetch External Data"

#### 3. –°–∏—Å—Ç–µ–º–∞ –Ω–∞—Ö–æ–¥–∏—Ç:

**ClinicalTrials.gov (5 trials):**
- NCT12345: Metformin in T2DM (Phase 3, Completed)
- NCT23456: SGLT2 inhibitor in T2DM (Phase 2, Recruiting)
- NCT34567: DPP-4 inhibitor in T2DM (Phase 3, Completed)

**PubMed (8 publications):**
- "DPP-4 inhibitors for T2DM: Meta-analysis" (NEJM, 2024)
- "AST-202 preclinical pharmacology" (J Pharmacol, 2023)
- "Glycemic control in T2DM: Current approaches" (Diabetes Care, 2024)

**openFDA (3 safety reports):**
- Hypoglycemia: 45 reports
- Nausea: 123 reports
- Headache: 89 reports

#### 4. User –≥–µ–Ω–µ—Ä–∏—Ä—É–µ—Ç IB

#### 5. AI —Å–æ–∑–¥–∞–µ—Ç IB —Å —ç—Ç–∏–º–∏ –¥–∞–Ω–Ω—ã–º–∏:

```markdown
# INVESTIGATOR'S BROCHURE
## AST-202 for Type 2 Diabetes Mellitus

### 7.3 EFFICACY

**Evidence from Published Literature:**

1. DPP-4 inhibitors for Type 2 Diabetes: A Meta-analysis
   (Johnson M et al., NEJM, 2024-02-15)
   
   Meta-analysis of 25 RCTs showed DPP-4 inhibitors reduce 
   HbA1c by -0.7% to -1.2% vs placebo. Well-tolerated with 
   low hypoglycemia risk.

2. AST-202 Preclinical Pharmacology Study
   (Smith J et al., J Pharmacol, 2023-11-20)
   
   AST-202 demonstrated potent and selective DPP-4 inhibition 
   (IC50 = 2.3 nM). In diabetic mice, AST-202 reduced HbA1c 
   by 1.8% at 10mg/kg dose.

**Evidence from Clinical Trials:**

- Study of Metformin in Type 2 Diabetes (NCT12345678)
  Phase: Phase 3 | Status: Completed
  Primary Outcome: HbA1c reduction at 24 weeks
  Enrollment: 500 participants
  Results: Mean HbA1c reduction -1.5% vs placebo (p<0.001)

- Study of DPP-4 Inhibitor in T2DM (NCT34567890)
  Phase: Phase 3 | Status: Completed
  Primary Outcome: HbA1c change from baseline
  Enrollment: 800 participants
  Results: HbA1c reduction -0.9% with good tolerability

### 7.4 SAFETY AND TOLERABILITY

**Safety Data from FDA Adverse Event Reporting:**

Common Adverse Events (from post-marketing surveillance):
- Hypoglycemia: 45 reports (mostly mild-moderate, serious: 8%)
- Nausea: 123 reports (non-serious, transient)
- Headache: 89 reports (non-serious, self-limiting)
- Dizziness: 67 reports (non-serious)
- Diarrhea: 54 reports (non-serious)

**Analysis:**
The safety profile is consistent with the DPP-4 inhibitor 
class. Hypoglycemia risk is low when used as monotherapy. 
Most adverse events are mild and transient.
```

---

## ‚úÖ –ü—Ä–µ–∏–º—É—â–µ—Å—Ç–≤–∞

### 1. **–î–ª—è Medical Writers:**
- ‚è±Ô∏è –≠–∫–æ–Ω–æ–º–∏—è 4-6 —á–∞—Å–æ–≤ –Ω–∞ –ø–æ–∏—Å–∫ references
- üìö –ê–≤—Ç–æ–º–∞—Ç–∏—á–µ—Å–∫–∏–π literature review
- ‚úÖ –ê–∫—Ç—É–∞–ª—å–Ω—ã–µ –¥–∞–Ω–Ω—ã–µ (real-time API calls)

### 2. **–î–ª—è Regulatory Reviewers:**
- üìä Evidence-based –¥–æ–∫—É–º–µ–Ω—Ç—ã
- üîç –ü—Ä–æ–∑—Ä–∞—á–Ω–æ—Å—Ç—å –∏—Å—Ç–æ—á–Ω–∏–∫–æ–≤ –¥–∞–Ω–Ω—ã—Ö
- ‚úÖ Compliance —Å guidelines

### 3. **–î–ª—è AI:**
- ü§ñ –õ—É—á—à–∏–π –∫–æ–Ω—Ç–µ–∫—Å—Ç ‚Üí –ª—É—á—à–∏–π output
- üìà –ë–æ–ª–µ–µ —Ç–æ—á–Ω—ã–µ —Ä–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏–∏
- üéØ –†–µ–ª–µ–≤–∞–Ω—Ç–Ω—ã–µ –ø—Ä–∏–º–µ—Ä—ã

### 4. **–î–ª—è –ë–∏–∑–Ω–µ—Å–∞:**
- üí∞ ROI: 4-6 —á–∞—Å–æ–≤ √ó $150/—á–∞—Å = $600-900 —ç–∫–æ–Ω–æ–º–∏–∏ –Ω–∞ –¥–æ–∫—É–º–µ–Ω—Ç
- üöÄ Faster time-to-market
- ‚úÖ –ú–µ–Ω—å—à–µ regulatory delays

---

## üéØ –ò—Ç–æ–≥–æ

**External Evidence - —ç—Ç–æ –∫–ª—é—á–µ–≤–∞—è —Ñ–∏—á–∞**, –∫–æ—Ç–æ—Ä–∞—è –ø—Ä–µ–≤—Ä–∞—â–∞–µ—Ç Asetria –∏–∑ "–ø—Ä–æ—Å—Ç–æ AI –≥–µ–Ω–µ—Ä–∞—Ç–æ—Ä–∞" –≤ **–ø—Ä–æ—Ñ–µ—Å—Å–∏–æ–Ω–∞–ª—å–Ω—ã–π –∏–Ω—Å—Ç—Ä—É–º–µ–Ω—Ç –¥–ª—è regulatory –¥–æ–∫—É–º–µ–Ω—Ç–æ–≤**.

### –ë–µ–∑ External Evidence:
```markdown
### 7.3 Efficacy
- Phase 1 studies showed safety and tolerability
- Phase 2 studies are planned
```
‚ùå –°–ª–∞–±–æ, –Ω–µ—Ç evidence, —Ä–µ–≥—É–ª—è—Ç–æ—Ä—ã –Ω–µ –ø—Ä–∏–º—É—Ç

### –° External Evidence:
```markdown
### 7.3 Efficacy

**Evidence from Published Literature:**
- Meta-analysis of 25 RCTs (NEJM, 2024): HbA1c -0.7% to -1.2%
- AST-202 preclinical study (J Pharmacol, 2023): HbA1c -1.8%

**Evidence from Clinical Trials:**
- NCT12345: Metformin Phase 3 (n=500): HbA1c -1.5% (p<0.001)
- NCT34567: DPP-4 inhibitor Phase 3 (n=800): HbA1c -0.9%

**Safety Data from FDA:**
- Hypoglycemia: 45 reports (8% serious)
- Nausea: 123 reports (transient)
```
‚úÖ –ü—Ä–æ—Ñ–µ—Å—Å–∏–æ–Ω–∞–ª—å–Ω–æ, evidence-based, –≥–æ—Ç–æ–≤–æ –∫ submission!

---

## üöÄ –ß—Ç–æ –¥–∞–ª—å—à–µ?

### –í–æ–∑–º–æ–∂–Ω—ã–µ —É–ª—É—á—à–µ–Ω–∏—è:

1. **–ë–æ–ª—å—à–µ –∏—Å—Ç–æ—á–Ω–∏–∫–æ–≤:**
   - EMA (European Medicines Agency)
   - WHO Clinical Trials Registry
   - Cochrane Database

2. **–£–º–Ω—ã–π –ø–æ–∏—Å–∫:**
   - Semantic search (–Ω–µ –ø—Ä–æ—Å—Ç–æ keywords)
   - Relevance scoring
   - Automatic deduplication

3. **–ö—ç—à–∏—Ä–æ–≤–∞–Ω–∏–µ:**
   - –ù–µ –¥–µ–ª–∞—Ç—å –ø–æ–≤—Ç–æ—Ä–Ω—ã–µ –∑–∞–ø—Ä–æ—Å—ã
   - Update —Ç–æ–ª—å–∫–æ –Ω–æ–≤—ã—Ö –¥–∞–Ω–Ω—ã—Ö

4. **Visualization:**
   - –ì—Ä–∞—Ñ–∏–∫ timeline –ø–æ—Ö–æ–∂–∏—Ö trials
   - Safety dashboard
   - Evidence quality score

---

**External Evidence = Competitive Advantage –¥–ª—è Asetria!** üéâ
